Alexander Eser
YOU?
Author Swipe
View article: Relation of Serum IGF-1 and IGFBP-3 Levels with Acute Exacerbation in Cystic Fibrosis
Relation of Serum IGF-1 and IGFBP-3 Levels with Acute Exacerbation in Cystic Fibrosis Open
Aim: Cystic fibrosis (CF) is an autosomal recessive genetic disorder primarily affecting the lungs and it is a leading cause of morbidity and mortality. Progressive lung disease and acute pulmonary exacerbations (PEx) are significant contr…
View article: Small airway resistance in obese and nonobese patients with obstructive sleep apnea syndrome using impulse oscillometry
Small airway resistance in obese and nonobese patients with obstructive sleep apnea syndrome using impulse oscillometry Open
Among obese OSAS patients, there is an increase in resistance in small airways as indicated by IOS values. IOS shows promise as a potential screening tool for diagnosing OSAS.
View article: Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases
Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases Open
Background: Substantial inter-and intra-individual variability of Infliximab (IFX) pharmacokinetics necessitates tailored dosing approaches. Here, we evaluated the performances of a Model Informed Precision Dosing (MIPD) Tool in forecastin…
View article: Issue Information
Issue Information Open
Aims and Scope: For more than 50 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacolog…
View article: Quantitative relationship between infliximab exposure and inhibition of C‐reactive protein synthesis to support inflammatory bowel disease management
Quantitative relationship between infliximab exposure and inhibition of C‐reactive protein synthesis to support inflammatory bowel disease management Open
Aim Quantitative and kinetic insights into the drug exposure‐disease response relationship might enhance our knowledge on loss of response and support more effective monitoring of inflammatory activity by biomarkers in patients with inflam…
View article: Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection
Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection Open
Treatment of patients with biologics such as infliximab may trigger development of antidrug antibodies, which are associated with faster drug clearance, reduced treatment efficacy, and increased risk of infusion‐related reactions. The aim …
View article: Issue Information
Issue Information Open
Aims and Scope: For more than 50 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacolog…
View article: P401 Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies
P401 Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies Open
Anti-drug antibodies (ADAs) to infliximab (IFX) are causative for loss of response due to accelerated drug clearance.1 Serum infliximab concentrations (SICs) of <3 μg are associated with an increased risk of ADA formation.2 Here we are ass…
View article: The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐<scp>TNF</scp>‐α naïve Crohn's disease
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐<span>TNF</span>‐α naïve Crohn's disease Open
Summary Background TNF α antagonists, including infliximab ( IFX ) and adalimumab ( ADA ), have revolutionised treatment for Crohn's disease. Studies comparing efficacy in patients with Crohn's disease naïve to TNF α antagonists are lackin…